Exemplis Discimus 2010, 154(1):3-7

Donec quam diam, fermentum et, consequat non, viverra sed, sem.

Melfina Fabiszaka,b
a Department of Oral and Maxillofacial Pathology, Duro University Hospital, Republic of Ansion
b Department of Epidemiology and Biostatistics, Ord Mantell Faculty Hospital, Republic of Tund

Background: Mauris ligula eros, condimentum vel, malesuada ac, sollicitudin in, urna. Suspendisse nibh nisl, iaculis non, rutrum fringilla, viverra bibendum, lacus. Aenean id metus at lorem ultricies pharetra. Mauris sed nunc consectetuer odio euismod placerat. Mauris pede leo, tristique eu, imperdiet in, posuere sit amet, velit. Praesent leo sapien, pellentesque vel, adipiscing vel, scelerisque interdum, nisl. Maecenas nunc massa, convallis ac, accumsan ornare, faucibus in, turpis. Fusce elit turpis, lacinia tristique, aliquet sit amet, blandit dictum, neque.

Methods and results: Pellentesque aliquet, magna a posuere tempor, lectus augue feugiat elit, eu sodales mi orci nec velit. Vestibulum eleifend, ante quis auctor commodo, tellus dolor viverra velit, ac cursus mauris est ut neque.

Conclusions: Aenean lectus lectus, tempor ut, scelerisque nec, tempus congue, nisl. Maecenas nunc massa, convallis ac, accumsan ornare, faucibus in, turpis. Praesent mi risus, aliquam at, venenatis ac, bibendum at, arcu. Ut leo dolor, mollis vel, convallis quis, lacinia vitae, lacus. Nam ac tortor pretium risus dapibus pulvinar. Vivamus vitae leo vel urna molestie placerat. Maecenas quis odio quis purus dapibus suscipit. Praesent nec enim vel elit sollicitudin bibendum.

Kµúčové slová: Aliquam ac diam, Nulla in odio, Ut quis magna

Vloľený: October 12, 2009; Přijatý: March 1, 2010; Uverejnené: March 1, 2010 

Zobrazi» celý článok

Referencie

  1. Martin JA, Hamilton BE, Ventura SJ et al. Births: final data for 2001. Natl Vital Stat Rep 2002; 51: 1102.
  2. ACOG American College of Obstetricians and Gynecologists. Prevention of RhD alloimmunization. ACOG practice bulletin no.4. Washington, DC, 1999.
  3. Fung KFK, Eason E, Crane J et al. Maternal-Fetal Medicine Committee, Genetics Committee. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 2003; 25: 765773.
  4. RANZCOG Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Guidelines for the use of RH D Immunoglobulin (Anti-D) in obstetrics in. Australia 2007. Available from: www.ranzcog.edu.au/publications/statements/Cobs6. pdf
  5. RCOG Royal College of Obstetrics and Gynaecology. United Kingdom. Green Top Guidelines 2002. Use of Anti-D immunoglobulin for Rh prophylaxis 2002. Available from: www.rcog.org.uk/ index.asp?PageID=512
  6. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. The Cochrane Database of Systematic Reviews, 2009, 3 (updated November 2008).
  7. Crowther C, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. The Cochrane Database of Systematic Reviews, 2009, 3 (updated November 2008).
  8. Bowman JM. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when shoud it be given? Am J Obstet Gynecol 1985; 151: 289294. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  9. Contreras M. The prevention of Rh haemolytic disease of the fetus and newborn general background. Br J Obstet Gynaecol 1998; 105: 710. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  10. Urbaniak S. The clinical application of anti-D prophylaxis. In: Hadley A, Soothill P. Alloimmune disorders of pregnancy: anaemia, thrombocytopenia and neutropenia in the fetus and newborn. Cambridge, UK: Cambridge University Press; 2002. p. 97120.
  11. Brambati B, Guercilena S, Bonacchi I et al. Feto-maternal transfusion after chorionic villus sampling: clinical implications. Hum Reprod 1986; 1: 3740.
  12. Augustson BM, Fong EA, Grey DE et al. Postpartum anti-D: can we safely reduce the dose? Med J Aust 2006; 184: 611613.
  13. Moise KJ Jr. Management of rhesus alloimunization in pregnancy. Obstet Gynecol 2002; 100: 600611. Prejs» k pôvodnému zdroju...
  14. Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does not predict excess fetal-maternal haemorrhage. Am J Obstet Gynecol 1987; 156: 154158. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  15. Sebring E, Polesky H. Fetomaternal hemorrhage: incidence, risk factors, time of occurence and clinical effects. Transfusion 1990; 30: 344357. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  16. Stedman C, Baudin J, White C et al. Use of the erythrocyte rosette test to screen for excessive fetomaternal hemorrhage in Rh negative women. Am J Obstet Gynecol 1986; 154: 13631369. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  17. Feldman N, Skoll A, Sibai B. The incidence of significant fetomaternal haemorrhage in patients undergoing cesarean section. Am J Obstet Gynecol 1990; 163: 855858. Prejs» k pôvodnému zdroju...
  18. Chilcott J, Lloyd JM, Wight J et al. A review of the clinical effectiveness and cost effectiveness of routine anti-D prophylaxies for pregnant women who are Rhesus (RhD) negative 2002, National Institute of Clinical Excelence, London.
  19. NHMRC National Health and Medical Research Council. Australia. National Blood Authority. Gudelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics 2003.
  20. RCOG Royal College of Obstetrics and Gynaecology. United Kingdom. Anti-D Immunoglobulin for Rh Prophylaxis 2002. Available from: http://www.rcog.org.uk/womens-health/clinicalguidance/ use-anti-d-immunoglobulin-rh-prophylaxis-green-top-22
  21. RCOG Royal College of Obstetrics and Gynaecology. United Kingdom. NICE National Institute for Clinical Excellence's Technology Appraisal Guidance No 156. Routine antenatal anti- D prophylaxis for women who are rhesus D negative, August 2008 (Expected date of next issue May 2011). Available from: http://www.nice.org.uk/nicemedia/pdf/ TA156Guidance.pdf Available from: http://www.nice.org.uk/TA156
  22. Moise KJ Jr. Prevention of Rh (D) alloimmunization. The UpToDate Database of Systematic Reviews 2008 (updated April 2008). Available from: www.uptodate.com
  23. Moise KJ Jr. Pathogenesis and prenatal diagnosis of Rhesus (Rh) alloimmunization. The UpToDate Database of Systematic Reviews 2008 (updated April 2008). Available from: www.uptodate.com
  24. Kumar S. Universal RHD genotyping in fetuses. BMJ 2008; 336: 7834. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  25. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant woman: prospective feasibility study. BMJ 2008; 336: 8168. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  26. Szczepura A, Bonsel G, Krauth Ch, Osipenko L, Haverkamp A. Is fetal RHD typing in all RhD negative women cost effective? BMJ 2008; 336: 906. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  27. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat. Diagn. 2009; 29: 101107. Prejs» k pôvodnému zdroju...
  28. INTERNATIONAL FORUM: Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, Rouger P, Morelati F, Tantalo V, Fujii T, de Haas M, van der Schoot CE, Overbeeke M, Koelewijn J, Bonsel G, Vrijkotte T, Zupańska B, Martin-Vega C, Parra Lopez R, de Silva M, Contreras M, Panzer S, Ulm B, Mayr WR. Current status of immunoprophylaxis with anti-D immunoglobulin. Vox Sang. 2003; 85: 328337.

Spä» na obsah